Scarica l'app Stockscreener
184.18
0.00%
0.00
Dopo l'orario di chiusura:
184.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$184.18
Aprire:
$184.18
Volume 24 ore:
540.40K
Relative Volume:
0.88
Capitalizzazione di mercato:
$9.42B
Reddito:
$638.50M
Utile/perdita netta:
$-183.17M
Rapporto P/E:
-49.86
EPS:
-3.6943
Flusso di cassa netto:
$-93.89M
1 W Prestazione:
+6.35%
1M Prestazione:
+18.00%
6M Prestazione:
+42.14%
1 anno Prestazione:
+77.39%
Intervallo 1D:
$179.57
$185.05
Intervallo di 1 settimana:
$172.02
$185.05
Portata 52W:
$96.09
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
184.18 | 9.42B | 638.50M | -183.17M | -93.89M | -3.6943 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
axsm stock overview: Axsome Therapeutics (AXSM) - Bitget
AXSM SEC FilingsAxsome Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Maintains Axsome Therapeutics (AXSM) Buy Recommendation - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Update Recap: How does Axsome Therapeutics Inc compare to its peers2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Axsome Is Priced For Perfection Ahead Of Auvelity's Alzheimer's Agitation Decision - Seeking Alpha
Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Aug Big Picture: Does Axsome Therapeutics Inc outperform in volatile markets2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge - Yahoo Finance
Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test - Yahoo Finance
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity - simplywall.st
Today's Analyst Ratings for Axsome Therapeutics (AXSM) | AXSM St - GuruFocus
UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says - marketscreener.com
UBS raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda - Legal Desire Media and Insights
Franklin Street Advisors Inc. NC Invests in Axsome Therapeutics - National Today
Why Axsome Therapeutics Stock Is Suddenly Sinking - TipRanks
Franklin Street Advisors Inc. NC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 - Sahm
Axsome’s Decade of 33% Returns Puts Focus on $16 Billion Pipeline - NAI500
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Is This Healthcare Stock a Millionaire Maker? - AOL.com
(AXSM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics (AXSM) Q2 2024 earnings summary - Quartr
AXSM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market! - Smartkarma
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome Acquires Global Rights to TAK-063 from Takeda - Intellectia AI
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $260 - Moomoo
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect - The Pharma Letter
AXSM Technical Analysis & Stock Price Forecast - intellectia.ai
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - Sahm
Biopharma bites: Axsome adds an asset from Takeda, IO Biotech's farewell, and Evotec's new commercial leader - FirstWord Pharma
Takeda (TAK) Sells Rights to Schizophrenia Drug to Axsome - GuruFocus
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Axsome Therapeutics Acquires Global Rights to Balipodect, a Selective PDE10A Inhibitor, for Schizophrenia and Neuropsychiatric Disorders 1 - minichart.com.sg
Axsome acquires global rights to Takeda’s balipodect - TipRanks
Axsome acquires global rights to balipodect from Takeda By Investing.com - Investing.com Canada
Axsome Therapeutics Acquires Exclusive Global Rights to Balipodect from Takeda - marketscreener.com
Axsome Therapeutics acquires balipodect, gains global rights and plans Phase 3-enabling work for schizophrenia - TradingView — Track All Markets
Axsome acquires global rights to balipodect from Takeda - Investing.com
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Axsome Therapeutics Incto Begin Phase 3 Tr - Moomoo
Axsome Therapeutics Acquires Selective PDE10A Inhibitor - GlobeNewswire
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):